GlassScriptPhysician profile
Sean P Hailey
NPI 1245405158
$2,605.63
in general payments reported to CMS, 2019-2025
30 companies · $882 in 2025
The $882 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $310 · 2023: $706 · 2024: $561 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $317.57 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $241.01 | 2022-2025 | |
| Pfizer INC. | $224.94 | 2022-2025 | |
| Novo Nordisk INC | $192.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $177.50 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $160.19 | 2023-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $136.48 | 2022 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $89.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.77 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $85.27 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $71.20 | 2023-2025 | Eliquis, Camzyos |
| Insulet Corporation | $66.94 | 2025 | Omnipod |
| Edwards Lifesciences Corporation | $66.26 | 2023-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $55.15 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $53.20 | 2024 | Voquezna |
| Baxter Healthcare | $52.57 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Dexcom, INC. | $46.15 | 2022-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $42.50 | 2021-2022 | |
| Astellas Pharma US INC | $39.55 | 2024 | Veozah |
| Daiichi Sankyo INC. | $39.29 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $36.87 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Specialty L.P. | $35.94 | 2024 | Yupelri |
| Shield Therapeutics INC | $28.20 | 2023 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $27.97 | 2024-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.36 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.51 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $19.85 | 2025 | Neffy |
| Ibsa Pharma INC. | $17.35 | 2025 | Tirosint, Licart, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Hailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.